Hepatitis B Seroprevalence in 10-25-year-olds in Mexico - the 2012 National Health and Nutrition Survey (ENSANUT) Results

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2018 Nov 2

PMID 30380981

Citations 6

Authors

Hugo Lopez-Gatell

Lourdes Garcia-Garcia

Gabriela Echaniz-Aviles

Pablo Cruz-Hervert

Maria Olamendi-Portugal

Deyanira Castaneda-Desales

Miguel Angel Sanchez-Aleman

Martin Romero-Martinez

Rodrigo DeAntonio

Maria Yolanda Cervantes-Apolinar

Ricardo Cortes-Alcala

Celia Alpuche-Aranda

Affiliations

Soon will be listed here.

Abstract

Objectives: To estimate hepatitis B virus (HBV) seroprevalence from natural infection or vaccination in 10-25-year-olds in Mexico, using the 2012 National Health and Nutrition Survey (ENSANUT).

Methods: Randomly selected serum samples (1,581) from adolescents and young adults, representative of 38,924,584 Mexicans, were analyzed to detect hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (anti-HBs) and hepatitis B core antibody (anti-HBc). Weighted HBV seroprevalence in the Mexican population and association with sociodemographic variables were calculated.

Results: Overall weighted seroprevalence from natural infection (positive for anti-HBs and anti-HBc) was 0.23% (95% confidence interval [95% CI] 0.10-0.52). No HBsAg was detected, indicating no acute or chronic infection. Vaccine-derived immunity (positive ≥ 10.0 mIU/ml for anti-HBs and negative to anti-HBc) was 44.7% (95% CI: 40.2-49.4) overall; lower in persons aged 20-25 years (40.83%) than in persons aged 10-19 years (47.7%). Among the population analyzed, 54.2% (95% CI: 49.6-58.8) were seronegative to HBV (negative for all three markers) and no sociodemographic risk factors were identified.

Conclusions: HBV seroprevalence from natural infection was low. Vaccination-induced immunity was higher among Mexican adolescents than young adults, possibly due to vaccination policies since 1999.

Citing Articles

An Update on Viral Hepatitis B and C in Mexico: Advances and Pitfalls in Eradication Strategies.

Campos-Valdez M, Castro-Garcia M, Ramos-Marquez M, Gurrola-Diaz C, Salazar-Montes A, Sanchez-Orozco L Microorganisms. 2024; 12(7).

PMID: 39065136 PMC: 11279215. DOI: 10.3390/microorganisms12071368.

Hepatitis B Virus Genotype H: Epidemiological, Molecular, and Clinical Characteristics in Mexico.

Panduro A, Roman S, Laguna-Meraz S, Jose-Abrego A Viruses. 2023; 15(11).

PMID: 38005864 PMC: 10675821. DOI: 10.3390/v15112186.

Hepatitis B antibody levels after different doses of hepatitis B vaccination: a retrospective study based on hospitalized children.

Chai Y, Tang J, Su Y, Xuan K, Xu L, Hao J Epidemiol Infect. 2023; 151:e186.

PMID: 37881897 PMC: 10644064. DOI: 10.1017/S0950268823001747.

Hepatitis B Immunization Status in Children with Chronic Kidney Disease: Experience at a Single Center, Egypt.

Youssef D, El-Shal A, Elbehidy R, Fouda M, Shalaby S, El Hawy L J Clin Med. 2023; 12(5).

PMID: 36902652 PMC: 10003117. DOI: 10.3390/jcm12051864.

Patient sexuality disclosure experience and associations with clinical sexual health outcomes among HIV-negative men who have sex with men in Mexico.

Algarin A, Wiginton J, Sanchez T, Hernandez-Avila M, Baruch-Dominguez R, Smith L Prev Med. 2022; 163:107225.

PMID: 36029923 PMC: 9985480. DOI: 10.1016/j.ypmed.2022.107225.

References

Schweitzer A, Horn J, Mikolajczyk R, Krause G, Ott J . Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015; 386(10003):1546-55. DOI: 10.1016/S0140-6736(15)61412-X. View

Juarez-Figueroa L, Uribe-Salas F, Conde-Gonzalez C . Heterogeneous distribution of hepatitis B serological markers in rural areas of Mexico. Salud Publica Mex. 2011; 53 Suppl 1:S26-31. View

Schillie S, Vellozzi C, Reingold A, Harris A, Haber P, Ward J . Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2018; 67(1):1-31. PMC: 5837403. DOI: 10.15585/mmwr.rr6701a1. View

Roman S, Panduro A, Aguilar-Gutierrez Y, Maldonado M, Vazquez-Vandyck M, Martinez-Lopez E . A low steady HBsAg seroprevalence is associated with a low incidence of HBV-related liver cirrhosis and hepatocellular carcinoma in Mexico: a systematic review. Hepatol Int. 2009; 3(2):343-55. PMC: 2716764. DOI: 10.1007/s12072-008-9115-9. View

Roman S, Tanaka Y, Khan A, Kurbanov F, Kato H, Mizokami M . Occult hepatitis B in the genotype H-infected Nahuas and Huichol native Mexican population. J Med Virol. 2010; 82(9):1527-36. DOI: 10.1002/jmv.21846. View

Romero-Martinez M, Shamah-Levy T, Franco-Nunez A, Villalpando S, Cuevas-Nasu L, Gutierrez J . [National Health and Nutrition Survey 2012: design and coverage]. Salud Publica Mex. 2014; 55 Suppl 2:S332-40. View

Diaz-Ortega J, Ferreira-Guerrero E, Trejo-Valdivia B, Maria Tellez-Rojo M, Ferreyra-Reyes L, Hernandez-Serrato M . [Vaccination coverage in children and adolescents in Mexico: vaccinated, under vaccinated and non vaccinated]. Salud Publica Mex. 2014; 55 Suppl 2:S289-99. View

Trepo C, Chan H, Lok A . Hepatitis B virus infection. Lancet. 2014; 384(9959):2053-63. DOI: 10.1016/S0140-6736(14)60220-8. View

Fourati S, Cristescu R, Loboda A, Talla A, Filali A, Railkar R . Pre-vaccination inflammation and B-cell signalling predict age-related hyporesponse to hepatitis B vaccination. Nat Commun. 2016; 7:10369. PMC: 4729923. DOI: 10.1038/ncomms10369. View

10.

Cisneros-Castolo M, Hernandez-Ruiz L . Prevalence of hepatitis B virus infection and related risk factors in a rural community of Mexico. Am J Trop Med Hyg. 2002; 65(6):759-63. DOI: 10.4269/ajtmh.2001.65.759. View

11.

Alvarez A, Perez-Vilar S, Pacis-Tirso C, Contreras M, El Omeiri N, Ruiz-Matus C . Progress in vaccination towards hepatitis B control and elimination in the Region of the Americas. BMC Public Health. 2017; 17(1):325. PMC: 5392937. DOI: 10.1186/s12889-017-4227-6. View

12.

Lopez-Balderas N, Bravo E, Camara M, Hernandez-Romano P . Seroprevalence of hepatitis viruses and risk factors in blood donors of Veracruz, Mexico. J Infect Dev Ctries. 2015; 9(3):274-82. DOI: 10.3855/jidc.4812. View

13.

Yang S, Tian G, Cui Y, Ding C, Deng M, Yu C . Factors influencing immunologic response to hepatitis B vaccine in adults. Sci Rep. 2016; 6:27251. PMC: 4914839. DOI: 10.1038/srep27251. View

14.

Gonzalez-Huezo M, Sanchez-Hernandez E, Camacho M, Mejia-Lopez M, Rebollo-Vargas J . [Prevalence of positive markers for hepatitis B (HBV Ags) and hepatitis C (Anti-HCV) in health personnel at the Social Security Institute of Mexico State and Municipalities]. Rev Gastroenterol Mex. 2010; 75(3):293-8. View

15.

Van Damme P . Long-term Protection After Hepatitis B Vaccine. J Infect Dis. 2016; 214(1):1-3. DOI: 10.1093/infdis/jiv750. View

16.

Liang T . Hepatitis B: the virus and disease. Hepatology. 2009; 49(5 Suppl):S13-21. PMC: 2809016. DOI: 10.1002/hep.22881. View

17.

Simons B, Spradling P, Bruden D, Zanis C, Case S, Choromanski T . A Longitudinal Hepatitis B Vaccine Cohort Demonstrates Long-lasting Hepatitis B Virus (HBV) Cellular Immunity Despite Loss of Antibody Against HBV Surface Antigen. J Infect Dis. 2016; 214(2):273-80. PMC: 4918827. DOI: 10.1093/infdis/jiw142. View

18.

Tanaka J . Hepatitis B epidemiology in Latin America. Vaccine. 2000; 18 Suppl 1:S17-9. DOI: 10.1016/s0264-410x(99)00455-7. View